PVCT
Provectus Biopharmaceuticals, Inc.
$0.07
+0.00 (+4.48%)
At close · Jul 8
Market Cap
$29.42M
Shares
420,279,879
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$336.11K
-45.5%
FY2025
Net Income
-$5.43M
-14.8%
FY2025
Gross Margin
61.73%
FY2011
Operating Margin
-1575.32%
-840.9pp
FY2025
Diluted EPS
-$0.01
0%
FY2025
Operating Cash Flow
-$3.33M
-1.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $336.11K | $617.14K | $557.71K | $989.04K | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $39.76K | — | — | — | — | — | — | — | — | |
| — | -$210.36K | -$239.07K | -$216.21K | -$163.69K | -$961.7K | — | — | — | — | — | — | — | -$8.1M | -$8.1M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $15.22K | $15.22K | $15.22K | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $24.54K | $24.54K | $24.54K | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 61.73% | — | — | — | — | — | — | — | — | |
| $1.83M | $1.9M | $2.05M | $1.75M | $2.39M | $2.61M | $2.81M | $4M | $4.75M | $8.2M | $8.21M | $11.38M | $5.81M | $3.6M | $5.01M | $8.81M | $8.42M | $4.91M | — | — | — | — | — | — | |
| $3.67M | $3.73M | $3.1M | $1.71M | $2.03M | $2.06M | $2.15M | $2.3M | $3.31M | $5.12M | $16.3M | $13.27M | $11M | $8.76M | $8.66M | $11.96M | $11.6M | $6.75M | — | — | — | — | — | — | |
| — | — | — | — | — | — | $228.11K | $671.12K | $671.12K | $671.12K | $671.12K | $671.12K | $671.12K | $671.12K | $671.12K | $671.12K | $671.12K | — | — | — | — | — | — | — | |
| $5.5M | $5.63M | $5.15M | $3.46M | $4.42M | $4.67M | $4.96M | $6.3M | $8.05M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$5.44M | -$5.29M | -$4.53M | -$2.9M | -$3.43M | -$4.67M | -$4.96M | -$6.3M | -$8.05M | -$13.32M | -$24.51M | -$24.65M | -$12.63M | -$13.03M | -$14.34M | -$21.44M | -$20.69M | -$12.33M | — | — | — | — | — | — | |
| — | -1575.32% | -734.42% | -520.21% | -346.59% | — | — | — | — | — | — | — | — | — | — | -53929.78% | — | — | — | — | — | — | — | — | |
| — | $5338 | $13.59K | $5650 | $3409 | $961.7K | $1.75M | $1.46M | $969.72K | — | — | — | — | — | — | $8.1M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $4 | $3415 | $23.16K | $19.56K | $31.3K | $2126 | $4861 | $5645 | $1325 | $1347 | $1527 | $1202 | $3817 | — | — | — | — | — | — | |
| — | -$210.36K | -$229.75K | -$200.52K | -$126.74K | -$867.29K | -$1.71M | -$622.84K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$5.51M | -$4.77M | -$3.1M | -$3.55M | -$5.54M | -$6.68M | -$6.92M | -$8.15M | -$13.52M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| -$5.54M | -$5.43M | -$4.73M | -$3.1M | -$3.55M | -$5.54M | -$6.68M | -$6.92M | -$8.15M | -$13.52M | -$24.43M | -$24.5M | -$10.24M | -$27.7M | -$12.57M | -$19.43M | -$18.55M | -$12.32M | -$10.27M | -$10.01M | -$8.87M | -$11.76M | -$4.34M | -$3.16M | |
| — | -1615.81% | -766.85% | -556.16% | -359.41% | — | — | — | — | — | — | — | — | — | — | -48883.72% | — | — | — | — | — | — | — | — | |
| -$63.27K | -$74.27K | -$29.59K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | -$8.15M | -$13.53M | -$28.86M | -$24.5M | -$10.24M | -$28.89M | -$12.75M | -$19.68M | -$28.96M | -$12.32M | — | — | — | — | — | — | |
| -$5.58M | -$5.43M | -$4.73M | -$3.13M | -$3.56M | -$5.54M | -$6.69M | -$6.95M | -$8.15M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.01 | -$0.01 | -$0.01 | -$0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 420.28M | 419.81M | 419.51M | 419.47M | 408.22M | 393.25M | 386.59M | 382.34M | 369.23M | 233.85M | 195.66M | 175.83M | 132M | 112.99M | — | — | — | — | — | — | — | — | — |
| shares | — | 420.28M | 419.81M | 419.51M | 419.47M | 408.22M | 393.25M | 386.59M | 382.34M | 369.23M | 233.85M | 195.66M | 175.83M | 132M | 112.99M | — | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2013: $144K in buybacks.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Clinical Stage Biotechnology Segment | $336,108 | $617,140 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Clinical Stage Biotechnology Segment | -$5,294,765 | -$4,532,384 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Clinical Stage Biotechnology Segment | -1575.3% | -734.4% |